TAS-102 and Bevacizumab as salvage line chemotherapy for colorectal cancer - SOAC1701

Surgical Oncology Association in Chiba (SOAC)0 个研究点目标入组 45 人开始时间: 2018年3月20日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)contraindications for TAS-102 and BEvacizumab 2)previously received chemotherapy with TAS-102 3)severe drug allergy 4)pregnant woman or Possibility of the pregnant woman. male patient who hoping partner's pregnancy. 5)patient who has important clinical complications(symptomatic unstable ischemic heart disease, arrhythmia, acute myocardial infarction within 6 months, liver cirrhosis, renal failure, active gastrointestinal ulcer, ileus, uncontrolled diabetes, uncontrolled hypertension, etc.) 6)have pleural effusion and ascitic fluid with the treatment 7)previous hemoptysis (over 25ml of fresh blood) 8)current or previous (within the last 6 months) history of GI perforation 9)patient with thrombosis (within the last 6 months) 10)patient with bleeding tendency 11)synchronous or metachronous multiple malignancy within the last 5 year disease free interval 12)dicision of unsuitable for this study by the investigator

发起方

Surgical Oncology Association in Chiba (SOAC)